Related Experiment Video

Updated: Jul 17, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Identification of target antigens in specific immunotherapy for renal cell carcinoma

Yoshihiro Komohara1, Mamoru Harada, Yoshimi Arima

  • 1Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University, Fukuoka, Japan.

The Journal of Urology
|February 14, 2007
PubMed
Abstract

Insights

Researchers identified three key antigens (multidrug resistance-associated protein 3, enhancer of zeste homologue 2, and Her2/neu) expressed in renal cell carcinoma. Peptides from these antigens effectively stimulated cancer-fighting T cells, paving the way for new immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Effective immunotherapy for renal cell carcinoma (RCC) remains a challenge, potentially due to limited knowledge of target antigens.
  • Recent advancements in cancer immunotherapy for other malignancies highlight the need for specific targets in RCC.

Purpose of the Study:

  • To identify novel target antigens for renal cell carcinoma (RCC) immunotherapy.
  • To evaluate the potential of identified antigens to induce RCC-specific cytotoxic T lymphocytes (CTLs).

Main Methods:

  • Examined mRNA expression of cancer-associated antigens in five RCC cell lines.
  • Assessed the ability of antigen-derived peptides to induce CTLs from peripheral blood mononuclear cells of HLA-A24+ RCC patients.

Main Results:

  • Three antigens—multidrug resistance-associated protein 3 (MRP3), polycomb group protein enhancer of zeste homologue 2 (EZH2), and Her2/neu—were expressed in all tested RCC cell lines.
  • Six peptides from MRP3, EZH2, and Her2/neu successfully induced peptide-specific and RCC-reactive CTLs in HLA-A24+ patients.
  • Cytotoxicity was mediated by human leukocyte antigen class I-restricted and peptide-specific CD8+ T cells.

Conclusions:

  • Identified promising target antigens and peptides for potential RCC immunotherapy.
  • Findings support the development of novel immunotherapeutic strategies for renal cell carcinoma.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...